Compare Johnson & Johnson (JNJ) vs Mondaycom Ltd (MNDY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Mondaycom Ltd — how do they compare? Johnson & Johnson trades at $250.32 (market cap $598.96B), while Mondaycom Ltd trades at $75.59 (market cap $3.24B). The key difference: Johnson & Johnson is far larger — about 184.9× Mondaycom Ltd's market cap, and Johnson & Johnson pays a 2.15% dividend while Mondaycom Ltd pays none. Which is the better fit depends on your goals.
| JNJ | MNDY | |
|---|---|---|
Market Cap | $598.96B | $3.24B |
Volume | 6,156,228 | — |
Sector | Health | Technology |
52-Week High | $267.24 | $292.24 |
52-Week Low | $164.36 | $58.81 |
Enterprise Value | $631.90B | $2.21B |
Dividend Yield | 2.15% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $249.58, down 1.37% today, amid a generally bullish technical outlook with strong moving average signals. The company reported robust Q2 2026 earnings, beating EPS estimates and raising full-year guidance, with revenue growth to $94.19B in 2025 and a net income margin of 21.48%. Recent news highlights strong institutional interest and positive analyst sentiment, though the stock faces pressure from MedTech segment misses despite overall strength.
The outlook for JNJ remains positive, supported by solid fundamentals, a consistent dividend history, and upward revised earnings guidance. Key risks include competitive pressures in pharmaceuticals, regulatory hurdles, and execution challenges in the MedTech division. With a consensus price target of $279.33, representing ~12% upside, the stock offers a compelling opportunity for long-term investors, balanced by sector-specific volatility and macroeconomic factors.
Monday.com trades at $76.75, down 2.47% on the day, with technical indicators showing neutral signals. The company maintains strong fundamentals with consistent earnings beats, including Q1 2026 EPS of $1.15 beating expectations of $0.96. Revenue grew to $1.23 billion in 2025 with a healthy 89.05% gross margin. Analyst sentiment remains bullish with 76% buy ratings and a $115.50 consensus price target representing 50% upside potential. Recent news highlights institutional selling but positive coverage of the company's AI-driven work management platform.
The stock presents a compelling opportunity given its strong earnings track record, high analyst conviction, and attractive valuation discount to price targets. Key risks include competitive pressures in the SaaS space and the stock's high valuation multiples. The company's transition to a 'seats + credits' pricing model and AI integration provide growth catalysts, though investors should monitor execution against 2026 guidance and cash flow trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Mondaycom Ltd
Monday.com Ltd. is a cloud-based software company providing a Work OS (Operating System) that enables organizations to manage projects, processes, and daily work. The platform is highly customizable, enabling teams to build tailored applications and workflows for a range of use cases, from marketing and sales to software development and HR. monday.com serves clients across numerous industries, aiming to improve transparency, collaboration, and efficiency across the entire enterprise.
Read more on MNDY →
